Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2018-08-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders' meeting (临时股东大会) held on August 15, 2018. It includes voting results on various proposals related to share repurchase plans, authorization for the board to handle repurchase matters, and legal opinions confirming the meeting's compliance with laws and regulations. The document does not contain financial statements or management discussion but focuses on the voting outcomes and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4134 characters, which is sufficient to contain detailed voting results rather than a brief announcement. Therefore, the correct classification is DVA with high confidence.
2018-08-15 Chinese
关于前十名无限售条件股东情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from a company regarding the top 10 unrestricted shareholders as of two specific dates, including shareholding quantities and percentages. It also references a share repurchase plan with details on the amount and price limits. The content focuses on shareholder holdings and share repurchase intentions, not on financial results, management changes, or legal matters. The document length is short (1681 characters) and it is a formal announcement of shareholding information related to a share repurchase plan. This fits best with the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2018-08-10 Chinese
关于召开2018年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2018 second extraordinary general meeting of shareholders for 金宇生物技术股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items (notably a share repurchase proposal), registration procedures, and proxy authorization forms. The document does not contain financial statements or results but serves as a notice and procedural guide for the shareholders' meeting. It is not a report of voting results, nor a management or earnings report. Given the detailed nature of the meeting notice and the inclusion of proxy forms, this fits the category of a Proxy Solicitation & Information Statement (PSI), which provides shareholders with information and requests votes for meetings.
2018-08-08 Chinese
2018年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2018 Second Extraordinary General Meeting of Shareholders" of 金宇生物技术股份有限公司. It includes the meeting agenda, procedural notes, and detailed proposals related to a share repurchase plan and authorization for the board to handle repurchase matters. The content is focused on the meeting materials for a shareholders' meeting rather than the announcement of voting results or the meeting minutes. The document length is 2946 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no financial statement or detailed financial analysis present, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a voting results announcement (DVA) because it does not provide the results but rather the agenda and proposals. Therefore, the document best fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2018-08-08 Chinese
独立董事关于以集中竞价交易方式回购股份的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's plan to repurchase shares through centralized bidding. It references relevant regulations and confirms the legality, reasonableness, and benefits of the share repurchase. There is no financial data or detailed financial statements, nor is it a full report or announcement of financial results. The document is a formal opinion related to a share repurchase transaction, which aligns with the category of Transaction in Own Shares (POS). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is POS.
2018-07-30 Chinese
关于以集中竞价交易方式回购股份的预案
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through centralized bidding on the stock exchange. It includes specifics about the repurchase scale, price limits, duration, purpose, funding sources, and regulatory compliance. It also discusses risks related to the repurchase plan and includes financial data to justify the repurchase. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is clearly about a share buyback program, which fits the category of 'Transaction in Own Shares' (POS). The document length is 4020 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the correct classification is POS with high confidence.
2018-07-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.